[go: up one dir, main page]

NO20026008L - Fremgangsmåte for behandling av cardiovaskul¶re sykdommer - Google Patents

Fremgangsmåte for behandling av cardiovaskul¶re sykdommer

Info

Publication number
NO20026008L
NO20026008L NO20026008A NO20026008A NO20026008L NO 20026008 L NO20026008 L NO 20026008L NO 20026008 A NO20026008 A NO 20026008A NO 20026008 A NO20026008 A NO 20026008A NO 20026008 L NO20026008 L NO 20026008L
Authority
NO
Norway
Prior art keywords
procedure
treatment
cardiovascular diseases
cardiovascular
diseases
Prior art date
Application number
NO20026008A
Other languages
English (en)
Other versions
NO20026008D0 (no
Inventor
Neal Ivan Azrolan
Surendra Nath Sehgal
Steven Jay Adelman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20026008(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20026008D0 publication Critical patent/NO20026008D0/no
Publication of NO20026008L publication Critical patent/NO20026008L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20026008A 2000-06-16 2002-12-13 Fremgangsmåte for behandling av cardiovaskul¶re sykdommer NO20026008L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16
PCT/US2001/019179 WO2001097809A2 (en) 2000-06-16 2001-06-14 Method of treating cardiovascular disease using rapamycin

Publications (2)

Publication Number Publication Date
NO20026008D0 NO20026008D0 (no) 2002-12-13
NO20026008L true NO20026008L (no) 2002-12-13

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026008A NO20026008L (no) 2000-06-16 2002-12-13 Fremgangsmåte for behandling av cardiovaskul¶re sykdommer

Country Status (19)

Country Link
US (1) US20020013335A1 (no)
EP (1) EP1292302A2 (no)
JP (1) JP2003535899A (no)
KR (1) KR20030010710A (no)
CN (1) CN1436076A (no)
AR (1) AR028959A1 (no)
AU (2) AU2001268446B2 (no)
BR (1) BR0111601A (no)
CA (1) CA2412636A1 (no)
CZ (1) CZ20024115A3 (no)
EA (1) EA200300027A1 (no)
HU (1) HUP0301244A3 (no)
IL (1) IL153405A0 (no)
MX (1) MXPA02012410A (no)
NO (1) NO20026008L (no)
NZ (1) NZ523114A (no)
PL (1) PL365455A1 (no)
WO (1) WO2001097809A2 (no)
ZA (1) ZA200300418B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
TWI307277B (en) * 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (de) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
CN100435755C (zh) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US8871985B2 (en) 2010-03-15 2014-10-28 Exxonmobil Chemical Patents Inc. Processes for the production of alcohols
CA2926747A1 (en) * 2012-10-12 2014-04-17 Arlan RICHARDSON Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN105997940A (zh) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 炎症微环境响应性纳米药物、其制备方法及应用
CN117224557A (zh) * 2023-11-02 2023-12-15 中国人民解放军空军军医大学 柚皮苷联合雷帕霉素在制备治疗高脂血症的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
DK0994697T3 (da) * 1997-06-13 2005-02-14 Wyeth Corp Rapamycinformuleringer til oral indgivelse
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
MXPA02012410A (es) 2003-04-25
EA200300027A1 (ru) 2003-06-26
WO2001097809A3 (en) 2002-05-10
KR20030010710A (ko) 2003-02-05
HUP0301244A3 (en) 2005-01-28
HUP0301244A2 (hu) 2003-08-28
CZ20024115A3 (cs) 2003-06-18
NZ523114A (en) 2004-07-30
IL153405A0 (en) 2003-07-06
CA2412636A1 (en) 2001-12-27
JP2003535899A (ja) 2003-12-02
EP1292302A2 (en) 2003-03-19
CN1436076A (zh) 2003-08-13
US20020013335A1 (en) 2002-01-31
NO20026008D0 (no) 2002-12-13
AR028959A1 (es) 2003-05-28
WO2001097809A2 (en) 2001-12-27
AU2001268446B2 (en) 2005-08-11
ZA200300418B (en) 2004-04-15
PL365455A1 (en) 2005-01-10
BR0111601A (pt) 2003-07-01
AU6844601A (en) 2002-01-02

Similar Documents

Publication Publication Date Title
NO20026008L (no) Fremgangsmåte for behandling av cardiovaskul¶re sykdommer
NO20034590D0 (no) Fremgangsmåter for behandling av vaskul¶r sykdom
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
NO20031442D0 (no) Morfolin-acetamidderivater for behandling av inflammatoriske sykdommer
NO20031443L (no) Forbindelser nyttige for behandling av inflammatoriske sykdommer
NO20043000L (no) Et preparat for behandling av nevrocerebrovaskulaere sykdommer
DE60142473D1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
FI20000863A0 (fi) Uusi hoitomenetelmä
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
NO20045554L (no) Fremgangsmate for behandling av diabetes
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
IS6137A (is) Meðhöndlun á hugsýkistruflunum
NO20034123L (no) Fremgangsmåte for behandling av brennstoff
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
NO20024236L (no) Behandling av psoriasis
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
NO20012612L (no) Isonipecotamider for behandlingen av integrin-formidlede sykdommer
NO20030717L (no) Forbindelser for behandling av avhengighetsforstyrrelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application